EPHX2

(redirected from Soluble epoxide hydrolase)

EPHX2

A gene on chromosome 8p21 that encodes epoxide hydrolase-2. Epoxide hydrolases are critical biotransformation enzymes that activate and detoxify epoxides by breaking down aromatic compounds to dihydrodiols, which can be conjugated and excreted from the body.
 
Molecular pathology
EPHX2 mutations are associated with familial hypercholesterolaemia.
References in periodicals archive ?
Background: Soluble epoxide hydrolase (sEH) has been demonstrated to be a key enzyme involved in the pathologic development of several cardiovascular diseases and inflammation, and inhibition of sEH is therefore very helpful or crucial for the treatment of ischemia-reperfusion injury, cardiac hypertrophy, hypertension and inflammation.
The study, supported by the British Heart Foundation, used mice to investigate the process by which these nitro fatty acids lower blood pressure, looking at whether they inhibited an enzyme known as soluble Epoxide Hydrolase which regulates blood pressure.
Oxylipins that are metabolized by the CYP enzymes are called epoxides, which can be further metabolized by the soluble epoxide hydrolase enzyme into diols.
Recombinant human soluble epoxide hydrolase (sEH) was produced in a baculovirus expression system (Beetham et al.
today announced the presentation of three posters that validate the mechanistic activity and therapeutic potential of the company's lead drug candidate, AR9281, an orally-administered soluble epoxide hydrolase (sEH) inhibitor that is in a Phase II clinical program for the treatment of type 2 diabetes.
Earlier research had suggested that a troublesome enzyme, called soluble epoxide hydrolase, degrades natural inflammation inhibitors known as epoxyeicosatrienoic acids (EETs).
today announced the initiation of a Phase IIa clinical trial for AR9281, an orally- administered soluble epoxide hydrolase (s-EH) inhibitor being developed for the treatment of type 2 diabetes.
Substituted ureas and carbamates are mechanistic inhibitors of the soluble epoxide hydrolase (sEH).
The new study has revealed that analgesia mediated by inhibitors of the enzyme, soluble epoxide hydrolase (sEH), is dependent on a pain-mediating second messenger known as cyclic adenosinemonophosphate or cAMP.
today announced positive top line Phase I results for AR9281, an orally-administered soluble epoxide hydrolase (s-EH) inhibitor for the treatment of metabolic syndrome.
a privately-held biopharmaceutical company developing first-in-class soluble epoxide hydrolase (s-EH) inhibitors, today named D.
Arete Therapeutics is uniquely positioned to develop its pipeline of novel soluble epoxide hydrolase inhibitors for multiple disease indications and I look forward to applying my experience to build on the strong foundation and take the company to the next level of strategic and scientific excellence," said Dr.